DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity

Area of Science:

• Oncology
• Cancer Therapeutics
• Molecular Biology

Background:

• Tumor-associated mucin-1 (TA-MUC1) is a cancer-specific glycoform of MUC1.
• TA-MUC1 is highly expressed in epithelial cancers, presenting a therapeutic target.
• Aberrant glycosylation of MUC1 leads to TA-MUC1 expression on cancer cells.

Purpose of the Study:

• To develop and evaluate DS-3939a, a novel antibody-drug conjugate (ADC) targeting TA-MUC1.
• To assess the preclinical pharmacological activity of DS-3939a in vitro and in vivo.
• To investigate the potential of DS-3939a as a targeted cancer therapy.

Main Methods:

• Immunohistochemistry on clinical tumor tissue microarrays to assess TA-MUC1 expression.
• In vitro studies to evaluate DS-3939a binding, cytotoxicity, and apoptosis induction in cancer cells.
• In vivo evaluation of DS-3939a efficacy in TA-MUC1-positive cell line-derived and patient-derived xenograft models.

Main Results:

• TA-MUC1 expression was confirmed in various cancers, notably bladder, lung, and breast cancers.
• DS-3939a demonstrated specific binding to TA-MUC1 and inhibited cancer cell growth via DNA damage and apoptosis.
• Significant anti-tumor effects and tumor regression were observed in multiple preclinical xenograft models, including against other cytotoxic ADCs.

Conclusions:

• DS-3939a is a promising TA-MUC1-targeting ADC with potent anti-tumor activity.
• These preclinical findings support the clinical utility of DS-3939a for treating TA-MUC1-expressing tumors.
• The ongoing phase I/II clinical study (NCT05875168) will further evaluate DS-3939a's therapeutic potential.